A Randomized Open Label Phase 2 Study of Denintuzumab mafodotin (SGN -CD19A)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
May 23, 2016
End Date
February 18, 2019
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
May 23, 2016
End Date
February 18, 2019